| human | Q5 |
| P2798 | Loop ID | 240601 |
| P496 | ORCID iD | 0000-0001-7751-6177 |
| P1053 | ResearcherID | D-5686-2018 |
| P69 | educated at | University of Zimbabwe College of Health Sciences | Q99298948 |
| P108 | employer | University of Zimbabwe College of Health Sciences | Q99298948 |
| P106 | occupation | author | Q482980 |
| researcher | Q1650915 | ||
| P21 | sex or gender | female | Q6581072 |
| Q34203520 | "I don't feel shy because I will be among others who are just like me…": The role of support groups for children perinatally infected with HIV in Zimbabwe |
| Q34687538 | A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa |
| Q36182253 | Adult Hematology and Clinical Chemistry Laboratory Reference Ranges in a Zimbabwean Population |
| Q34494986 | Antiretroviral treatment for children with peripartum nevirapine exposure |
| Q37033083 | Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy |
| Q38890298 | CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection. |
| Q28551494 | Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe |
| Q92827882 | Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation |
| Q39313084 | Cryptococcal Meningitis Presenting as a Complication in HIV-infected Children: A Case Series From Sub-Saharan Africa |
| Q37579031 | Effect of handrubbing using locally-manufactured alcohol-based handrubs in paediatric wards in Harare, Zimbabwe |
| Q52589311 | Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial. |
| Q38849598 | Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa |
| Q34346519 | Ethical and legal constraints to children's participation in research in Zimbabwe: experiences from the multicenter pediatric HIV ARROW trial |
| Q62486855 | Health Outcomes, Pathogenesis and Epidemiology of Severe Acute Malnutrition (HOPE-SAM): rationale and methods of a longitudinal observational study |
| Q90127430 | Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe |
| Q53681956 | Intestinal Integrity Biomarkers in Early Antiretroviral-Treated Perinatally HIV-1-Infected Infants. |
| Q56912547 | Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial |
| Q38871160 | Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy |
| Q97516851 | Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy |
| Q46866659 | Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial. |
| Q35054163 | Opportunities for improving the efficiency of paediatric HIV treatment programmes |
| Q56910418 | Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV |
| Q38869353 | Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda |
| Q37708677 | Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children |
| Q34200009 | Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission |
| Q35205900 | Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy |
| Q35126455 | Pubertal development in HIV-infected African children on first-line antiretroviral therapy. |
| Q60047372 | Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial |
| Q38852917 | Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis. |
| Q40144571 | Rheumatic fever and rheumatic heart disease among children presenting to two referral hospitals in Harare, Zimbabwe |
| Q30539434 | Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial |
| Q52709185 | Temporal Improvements in Long-Term Outcome in Care Among HIV Infected Children Enrolled in Public ART Care: An Analysis of Outcomes From 2004-2012 in Zimbabwe. |
| Q90705912 | The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa |
| Q28602123 | Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy |
| Q47133943 | Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial |
Search more.